

School of Medicine – São Paulo University (USP)

Av. Dr. Arnaldo, 455, Cerqueira César

Pacaembu – SP

CEP: 01246-903

November 12, 2021

Dear Editor and Reviewers,

Thank you for your valuable comments. Below are the answers:

1. It should be a case report instead of a letter to editor. So, this manuscript should be re-submitted as a case report.

-Answer: We thank the reviewer's consideration. We preferred to submit it as a "Letter to Editor" to share briefly our experience of rituximab in a refractory case with HIV-associated nemaline myopathy.

2. Nemaline myopathy isn't included in the list of indications of rituximab. Did the authors get the approval of both the patients and the ethics committee? If yes, the documentary evidences must be provided.

-Answer: According to the literature, nemaline myopathy-HIV usually has a good response to immunosuppressive therapy. However, our patient had refractory to glucocorticoid, and conventional immunosuppressives; therefore, despite off-label, and after patient consent, we introduced the rituximab as a possible option to promote disease induction.

3. The long-term prognosis of this treatment should be provided. So, major revision should be recommended for this manuscript."

-Answer: We added long-term prognosis in the present case.

Regards